Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil in Chinese Adolescents With Chronic Graft-versus-host Disease
NCT06616415Phase 4Completed
- Sponsor
- Sanofi
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by Sanofi. Primary endpoint: Plasma concentrations of belumosudil at Day 29. Started Dec 2024; status: completed.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06616415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616415.